During an FDA audit, inspectors discovered that an investigative site had repeatedly enrolled subjects into a trial without obtaining informed consent. Which of the following actions would most likely occur?
a. The site would be issued a Form 483 and Warning Letter
b. The audit would receive an NAI classification
c. The site would be issued an Information Letter, but no response would be required
d. The investigator would be barred for life from conducting FDA-regulated research